The move comes as the US government looks for new ways to bring down prescription drug costs while encouraging more domestic manufacturing. Branded pharmaceuticals are a major import category and policymakers have been under pressure to respond to criticism that American patients often pay more than people in other advanced economies for the same medicines.
Under the policy, patented drugs imported into the US face a 100% tariff if the manufacturer does not commit to building or expanding production facilities in the country and does not agree to match its US prices to the lowest level it offers in other developed markets. Officials indicate that this top tariff bracket may ultimately hit only a small number of companies or potentially none, because drugmakers have options to reduce their exposure. If a large pharmaceutical company pledges to invest in US manufacturing over the next few years, its tariff rate can drop to 20%, provided it completes the new facility before the end of the current presidential term, with the risk of higher tariffs if it falls behind schedule. Any company that both commits to US manufacturing and enters a “most-favoured nation” style pricing agreement with the administration can bring its tariff rate down to zero. The rules take effect in 120 days for major drug companies, giving them a window to decide whether to invest or sign pricing deals, while smaller firms have 180 days to make their investment commitments.
This approach looks like an attempt to use trade tools to reset how and where high-value medicines are made, but it also seems to introduce new uncertainty for global pharmaceutical supply chains and future drug pricing negotiations. If many companies choose to invest in US plants and accept lower tariffs, the policy could accelerate domestic production and potentially narrow international price gaps. If they resist, it could raise costs on specific imported treatments and test how far the US is willing to go in linking tariffs, manufacturing locations and pricing arrangements.
